H W Herr

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Defining bacillus Calmette-Guerin refractory superficial bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Urol 169:1706-8. 2003
  2. ncbi Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
  3. ncbi Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
  4. ncbi Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 187:435-7. 2012
  5. ncbi A re-staging transurethral resection predicts early progression of superficial bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:1194-8. 2006
  6. ncbi Civiale, stones and statistics: the dawn of evidence-based medicine
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 104:300-2. 2009
  7. ncbi A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1111-4. 2008
  8. ncbi 'I will not cut . . . ': the oath that defined urology
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    BJU Int 102:769-71. 2008
  9. ncbi Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 174:2134-7. 2005
  10. ncbi Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 105:314-6. 2010

Detail Information

Publications97

  1. ncbi Defining bacillus Calmette-Guerin refractory superficial bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Urol 169:1706-8. 2003
    ..CONCLUSIONS: A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory...
  2. ncbi Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..CONCLUSIONS: This study demonstrates that a history of BTCC (invasive or superficial) has an adverse effect on the prognosis of patients diagnosed with UTTCC independent of primary tumor stage...
  3. ncbi Defining optimal therapy for muscle invasive bladder cancer
    Harry W Herr
    Department of Urology and Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Cornell University Weill Medical College, New York, New York 10021, USA
    J Urol 177:437-43. 2007
    ..We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy...
  4. ncbi Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 187:435-7. 2012
    ..The outcome of intravesical bacillus Calmette-Guérin therapy was studied in patients with asymptomatic bacteriuria...
  5. ncbi A re-staging transurethral resection predicts early progression of superficial bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 97:1194-8. 2006
    ..To determine whether pathology on a re-staging transurethral resection (TUR) predicts the early progression of superficial bladder cancer...
  6. ncbi Civiale, stones and statistics: the dawn of evidence-based medicine
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 104:300-2. 2009
    ..Civiale's insights and methods espoused similar concepts and ideas driving today's new paradigm of evidence-based medicine...
  7. ncbi A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:1111-4. 2008
    ....
  8. ncbi 'I will not cut . . . ': the oath that defined urology
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    BJU Int 102:769-71. 2008
    ..To explore different interpretations of the clause embedded in the Hippocratic Oath, prohibiting surgery for stones, and its relevance for urology...
  9. ncbi Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 174:2134-7. 2005
    ..This study was an evaluation of whether restaging transurethral resection (TUR) of superficial bladder cancer improves the early response to bacillus Calmette-Guerin (BCG) therapy...
  10. ncbi Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 105:314-6. 2010
    ..Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b...
  11. ncbi Henry Wade (1876-1955): an early 20th century cancer researcher and pioneer urologist
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 98:514-8. 2006
  12. ncbi 'Crushing the stone': a brief history of lithotripsy, the first minimally invasive surgery
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 102:432-5. 2008
    ..To trace the history of lithotripsy, marking the start of minimally invasive surgery...
  13. ncbi The enlarged prostate: a brief history of its surgical treatment
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    BJU Int 98:947-52. 2006
  14. ncbi Pathologic evaluation of radical cystectomy specimens: a cooperative group report
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2470-5. 2004
    ..Their objective was to determine whether current practices conform to suggested pathology practice guidelines for reporting on radical cystectomy and pelvic lymph node specimens...
  15. ncbi Early history of endoscopic treatment of bladder tumors from Grunfeld's polypenkneipe to the Stern-McCarthy resectoscope
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Endourol 20:85-91. 2006
  16. ncbi Urine cytology after flexible cystoscopy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    BJU Int 96:796-7. 2005
    ..To correlate urine cytology findings before and after flexible cystoscopy...
  17. ncbi Franklin, Lavoisier, and Mesmer: origin of the controlled clinical trial
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 23:346-51. 2005
    ..Using intentional subject ignorance and sham interventions to investigate mesmerism, Franklin's commission provided a model for the controlled clinical trial...
  18. ncbi Surgical factors in the treatment of superficial and invasive bladder cancer
    Harry W Herr
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 32:157-64. 2005
    ..The challenge is how to get better at maximizing surgical efforts. The who and how of surgery in bladder cancer does indeed matter...
  19. ncbi Urethral injuries in the Civil War
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York, USA
    J Urol 173:1090-3. 2005
    ..We compiled all cases of urethral injury received in battle during the Civil War to detail their management and determine the outcome of treatment...
  20. ncbi Legacy of Edwin Beer: fulguration of papillary bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 173:1087-9. 2005
    ..Edwin Beer introduced the first endoscopic treatment of papillary bladder tumors in 1910. This historical review describes how his landmark discovery paved the way for office cystodiathermy to treat recurrent papillary tumors...
  21. ncbi A history of partial nephrectomy for renal tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 173:705-8. 2005
    ..This article records the history of nephron sparing surgery for renal tumors...
  22. ncbi Urological injuries in the Civil War
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York, USA
    J Urol 172:1800-4. 2004
    ..This study compiles all cases of urological injuries reported in the Civil War (1861 to 1865)...
  23. ncbi Hunter Holmes McGuire and the coffee pot spout procedure
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA
    J Urol 177:1250-3. 2007
    ..Hunter Holmes McGuire (1835 to 1900) was a Confederate surgeon who made a unique contribution to urology...
  24. ncbi Surgical management of renal tumors: a historical perspective
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 35:543-9; v. 2008
    ..Surgery for kidney cancer continues to evolve. This article traces the history of surgical management for renal tumors...
  25. ncbi Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability
    Harry Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 106:53-5. 2010
    ..Diagnosis (exploratory cohort) Level of Evidence 2b...
  26. ncbi 'Cutting for the stone': the ancient art of lithotomy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    BJU Int 101:1214-6. 2008
    ..Bladder stone was a common ailment plaguing mankind from antiquity to the 20th century. Largely forgotten today, lithotomy relieved the anguish of bladder stones and identified urology as a medical specialty nearly 2500 years ago...
  27. ncbi Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome
    H W Herr
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:1298-301. 1998
    ....
  28. ncbi Transurethral resection of muscle-invasive bladder cancer: 10-year outcome
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:89-93. 2001
    ..To determine the 10-year outcome of patients with muscle-invasive bladder cancer treated by transurethral resection (TUR) alone...
  29. ncbi History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:53-6. 2008
    ..We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer...
  30. ncbi Management of low grade papillary bladder tumors
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:1201-5; discussion 1205. 2007
    ..We evaluated the management and treatment outcomes of low grade papillary bladder tumors...
  31. ncbi Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 70:65-8. 2007
    ..To determine the influence of age on the outcomes of high-risk superficial bladder cancer treated with intravesical bacille Calmette-Guérin (BCG) therapy...
  32. ncbi Standardization of radical cystectomy: time to count and be counted
    Harry W Herr
    Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    BJU Int 94:481-2. 2004
  33. ncbi Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 60:32-6. 2011
    ..Bacillus Calmette-Guérin (BCG) is the standard intravesical treatment of high-risk noninvasive (Ta, T1, Tis) bladder cancer. Maintenance BCG is recommended for maximum efficacy...
  34. ncbi Paternity in men with stage I testis tumors on surveillance
    H W Herr
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:733-4. 1998
    ..We report long-term paternity in men with stage I testis tumors who were managed initially by surveillance...
  35. ncbi Urachal carcinoma: contemporary surgical outcomes
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:74-8; discussion 78. 2007
    ..We determined surgical outcomes in a contemporary series of patients who underwent surgery for urachal carcinoma...
  36. ncbi Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 106:1499-501. 2010
    ....
  37. ncbi Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 1275 York Avenue, New York, NY 10021, USA
    Eur Urol 54:126-32. 2008
    ..To determine the outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer...
  38. ncbi Role of re-resection in non-muscle-invasive bladder cancer
    Harry W Herr
    Memorial Sloan Kettering Cancer Center, New York, USA
    ScientificWorldJournal 11:283-8. 2011
    ..Our conclusions show thatrestaging TUR improves the outcomes of high-risk,non-muscle-invasive bladder neoplasms...
  39. ncbi The concept of lymph node density--is it ready for clinical practice?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1273-5; discussion 1275-6. 2007
    ..The concept of lymph node density (ratio of positive-to-total number of nodes examined) is reviewed as a prognostic factor for recurrence-free survival after cystectomy in patients with invasive bladder cancer...
  40. ncbi Ignorance is bliss: the Listerian revolution and education of American surgeons
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA
    J Urol 177:457-60. 2007
    ..Joseph Lister introduced antiseptic surgery in 1867. American surgeons, entrenched in the old ways of 19th century medicine, failed to adopt Lister's methods...
  41. ncbi Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 107:396-8. 2011
    ..To evaluate frequency of recurrences among patients with papillary bladder tumours followed sequentially with conventional white-light (WLI) cystoscopy and narrow-band imaging (NBI) cystoscopy...
  42. ncbi Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:75-9; discussion 79. 2007
    ..We determined whether pathological findings on restaging transurethral resection predict early stage progression of T1 bladder cancer...
  43. ncbi Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse
    F Rabbani
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:2020-5. 2001
    ..In contrast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of relapse and should be considered for primary chemotherapy...
  44. ncbi Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E. 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..CONCLUSIONS: In highly selected patients with invasive bladder cancer, partial cystectomy offers acceptable outcomes. Concomitant CIS and presence of metastases to regional lymph nodes predict advanced recurrence...
  45. ncbi A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  46. ncbi The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer
    S M Donat
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1580-4. 2001
    ..However, it did not have significant clinical impact or affect survival and should not be an absolute contraindication to urethral diversion...
  47. ncbi Surgical factors influence bladder cancer outcomes: a cooperative group report
    Harry W Herr
    Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 22:2781-9. 2004
    ..2; P =.0001) and fewer than 10 nodes removed (v > or = 10; OR, 5.1; P =.002). CONCLUSION: Surgical factors influence bladder cancer outcomes after cystectomy, after adjustment for pathologic factors and neoadjuvant chemotherapy usage...
  48. ncbi Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 166:1296-9. 2001
    ..We compared survival after early versus delayed cystectomy in patients with high risk superficial bladder tumors...
  49. ncbi Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival
    Zohar A Dotan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:2308-12; discussion 2313. 2007
    ..We evaluated risk factors for positive soft tissue surgical margins and the impact of soft tissue surgical margins on metastatic progression and disease specific survival in patients treated with radical cystectomy for bladder cancer...
  50. ncbi Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology (Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..Such information is important not only for the therapy and prognosis of individuals, but also for identifying those who may benefit from adjuvant chemotherapy...
  51. ncbi Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 61:105-8. 2003
    ..Such information is important not only for therapy and the prognosis of individuals, but also for identifying candidates for adjuvant chemotherapy...
  52. ncbi Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  53. ncbi Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance
    F Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:94-100. 2001
    ....
  54. ncbi Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance
    S M Donat
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1117-20. 2001
    ..Such direct silent tumor invasion of the prostate by superficial or endoscopically inapparent tumor is difficult to detect clinically by current biopsy methods. New methods of detection are necessary...
  55. ncbi Superiority of ratio based lymph node staging for bladder cancer
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 169:943-5. 2003
    ....
  56. ncbi Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  57. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  58. ncbi Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stage
    Farhang Rabbani
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue New York, NY 10021, USA
    Urol Int 84:14-22. 2010
    ....
  59. ncbi Outpatient flexible cystoscopy in men: a randomized study of patient tolerance
    H W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 165:1971-2. 2001
    ..1 after immediate cystoscopy versus 1.8 after delayed cystoscopy (p = 0.7). CONCLUSIONS: There was no difference in pain perception in men undergoing immediate or delayed outpatient flexible cystoscopy using the same local anesthetic...
  60. ncbi Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer
    H W Herr
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Medical College, Cornell University, New York, New York, USA
    J Urol 165:811-4. 2001
    ..Optimal candidates include those in whom the pre-chemotherapy sites of disease are restricted to the bladder and pelvis or regional lymph nodes, and who have a major response to chemotherapy...
  61. ncbi Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy
    Daniel W Lin
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 169:961-3. 2003
    ..CONCLUSIONS: There was no significant survival difference in patients followed and not followed with urethral washing. Longer followup and increased patient numbers are needed to determine the significance of these findings...
  62. ncbi Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality)
    H W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    BJU Int 92:187-8. 2003
  63. ncbi Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens
    B H Bochner
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 166:2295-6. 2001
    ..Such information is important for identifying patients who may benefit from adjuvant chemotherapy...
  64. ncbi Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra
    G Dalbagni
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 166:1759-61. 2001
    ..Local control seems to have improved. We must evaluate a larger cohort of patients to determine this impact of the combined modality on local control and patient survival...
  65. ncbi Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation
    Anuradha Gopalan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:659-68. 2009
    ..Detailed pathologic studies with clinical outcome correlation are few...
  66. ncbi Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer
    Guido Dalbagni
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 56:903-10. 2009
    ..To evaluate the indications for early and deferred cystectomy and to report the impact of this tailored approach on survival...
  67. ncbi Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
    Theresa M Koppie
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 112:2384-92. 2008
    ..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
  68. ncbi Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
    ..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
  69. ncbi Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  70. ncbi Radical cystectomy in octogenarians--does morbidity outweigh the potential survival benefits?
    S Machele Donat
    Department of Urology, the Genitourinary Oncology Service in the Department of Medicine MIM, and the Department of Epidemiology and Biostatistics AC, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:2171-7. 2010
    ..4% of those with similar stage disease age 65 to 79 years, reflecting concern for perioperative morbidity. We evaluated the morbidity and survival outcomes of octogenarians treated with radical cystectomy at a tertiary cancer center...
  71. ncbi Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
    ..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
  72. ncbi Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer
    Jaspreet S Sandhu
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    BJU Int 98:59-62. 2006
    ....
  73. ncbi Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  74. ncbi Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:636-9. 2004
    ..We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy...
  75. ncbi Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  76. ncbi Max Nitze, the cystoscope and urology
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 176:1313-6. 2006
    ..CONCLUSIONS: The legacy of discovery of Max Nitze established the specialty of urology and a legitimate claim as the father of urology...
  77. ncbi Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2370-5. 2002
    ....
  78. ncbi Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:281-5. 2007
    ....
  79. ncbi Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1777-80. 2003
    ..High fluid intake has been associated with a decreased risk of bladder cancer development in men. We evaluated whether higher fluid intake can impact tumor recurrence rates in patients with superficial bladder cancer...
  80. ncbi Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?
    H W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 88:683-5. 2001
    ....
  81. ncbi Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:482-5. 2006
    ..Further studies are warranted to assess the safety and efficacy of bacillus Calmette-Guerin instillations in critically immunocompromised patients...
  82. ncbi Impact of a second transurethral resection on the staging of T1 bladder cancer
    Guido Dalbagni
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 60:822-4; discussion 824-5. 2002
    ..Thirteen percent of the patients who underwent immediate cystectomy after restaging TUR had a pathologic stage greater than pT1. CONCLUSIONS: Understaging for T1 disease is negligible after restaging TUR...
  83. ncbi Radiographic versus pathologic size of renal tumors: implications for partial nephrectomy
    H W Herr
    Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Urology 58:157-60. 2001
    ....
  84. ncbi A comparison of hospital-based charges following partial and radical nephrectomy
    J M McKiernan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, C-1064, New York, NY 10021, USA
    Urol Oncol 7:3-6. 2002
    ..No difference was found in the complication rate for these procedures (p > .05). CONCLUSION: Hospital-based charges for radical and partial nephrectomy are similar at when performed at a tertiary care referral center...
  85. ncbi Immediate versus delayed outpatient flexible cystoscopy: final report of a randomized study
    H W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Can J Urol 8:1406-8. 2001
    ..8 after immediate cystoscopy versus 1.7 after delayed cystoscopy (p=5). CONCLUSION: There was no difference in pain perception among men undergoing an immediate or a delayed outpatient flexible cystoscopy using the same local anesthetic...
  86. ncbi Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Urol 168:978-80. 2002
    ..CONCLUSIONS: Urologists can usually identify noninvasive, low grade recurrent papillary tumors on followup cystoscopy that may be treated safely with outpatient fulguration...
  87. ncbi Rebuttal from author re: Axel Heidenreich. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ preserving therapy in carefully selected patients. Eur Urol 2008;54:21-23
    Harry W Herr
    Eur Urol 54:23-4. 2008
  88. ncbi Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ....
  89. ncbi Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC
    Wassim Kassouf
    Department of Urology and the Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:121-6. 2008
    ..To compare the utility of lymph node density (LND) with TNM nodal status in predicting disease-specific survival (DSS) after radical cystectomy...
  90. ncbi Bladder cancer. Clinical guidelines in oncology
    James E Montie
    J Natl Compr Canc Netw 4:984-1014. 2006
  91. ncbi Positive surgical margins at partial nephrectomy: predictors and oncological outcomes
    Ofer Yossepowitch
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:2158-63. 2008
    ..We combine data from 2 tertiary care intuitions, and report predictors of positive surgical margins and long-term oncological outcomes for patients with positive surgical margins...
  92. ncbi Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study
    Badrinath R Konety
    Department of Urology, Memorial Sloan-Kettering Cancer Center and Cornell University, New York, New York 10021, USA
    J Urol 171:709-13. 2004
    ..Positive surgical margin rates are low. This approach yielded good local control of disease, however impact on tumor recurrence and survival is not known...
  93. ncbi Is less radical cystectomy better, and how can we be sure?
    Harry W Herr
    J Urol 173:1063. 2005
  94. ncbi Pathologic evaluation of radical cystectomy specimens
    Harry W Herr
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer 95:668-9. 2002
  95. ncbi Use of urinary biomarkers for bladder cancer surveillance: patient perspectives
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1277-82; discussion 1282. 2007
    ..We assessed whether patients would accept a urine biomarker assay over flexible cystoscopy for monitoring bladder cancer...
  96. ncbi Re: Francesco Montorsi. A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur urol 2007;52:307-9
    Harry W Herr
    Eur Urol 53:3-4; author reply 1. 2008
  97. ncbi Low risk bladder tumors--less is more!
    Harry W Herr
    J Urol 179:13-4. 2008